REPORT FROM THE ENS 2008 – Glatiramer acetate significantly delays progression to clinically-definite MS (CDMS) in patients with clinically-isolated syndrome (CIS), according to data from the PRECISE trial (Comi et al. Abstract 059. J Neurol 2008;255(suppl 2): 10). The results were initially reported at the American Academy of Neurology 60th annual meeting, April 16, 2008.